Nε Page 10, line 27. Replace "sequences (□)" with --

sequences (▨)--.

Nε Page 10, line 28. Replace "(□)" with --(▦)--.

Page 10, line 29. Replace "(B) αG-SGC" with
--(B) α-SGC--.

Nε Page 10, line 34. Replace "(□)" with --(▨)--.

Nε Page 11, line 1. Replace "(□)" with --(▓)--.

Page 11, line 24. Replace "2 '" with --2--.

Page 14, line 9. Replace "MGF" with --MFG--.

Page 14, line 15. Replace "MGF-S" with --MFG-S--.

Page 14, line 20. Replace "MGF-S" with --MFG-S--.

Page 18, line 6. Replace "Psi2" with --Psi-2--.

Page 44, line 26. Replace "t Crip" with --Psi-CRIP--.

Page 44, line 27. Replace "t Crip" with --Psi-CRIP--.

Page 47, lines 31-32. Replace "αG-SGC" with --α-SGC--.

Page 48, line 7. Replace "αG-SGC" with --α-SGC--.

IN THE CLAIMS

Please cancel Claims 5, and 32-34, without prejudice. The Applicants reserve the right to pursue the inventions defined by canceled claims 32-34 in a continuation application.

Claim 1 (amended). A recombinant retroviral vector, said vector comprising [in operable combination]:

a) a 5' LTR [and a 3' LTR] derived from a retrovirus of interest; [,and an]

b) a splice donor site located 3' to said 5' LTR;

c) a Psi packaging site located 3' to said splice donor site;

d) a splice acceptor site located 3' to said Psi packaging site; [and]

e) an insertion site for a gene of interest located 3' to said splice acceptor site;

f) a 3' LTR derived from a retrovirus of interest located 3' to said insertion site; and

g) wherein said vector does not contain a complete selectable marker gene, or a complete gag, env, or pol gene between said 5' and 3' LTRs.

Claim 2, line 3. After "sequence", insert --adjacent to said Psi packaging site--.

PEMP-45899.1